Diabetes and hypertension: the bad companions.

Lancet Lond Engl. 380: 601-610

Correction to: diabetes, cardiovascular disease and the microcirculation.

Cardiovasc Diabetol. 20: 120

[Hypertension and diabetes].

Rev Med Liege. 60: 572-577Oparil S Acelajado MC Bakris GL et al.

Hypertension.

Nat Rev Dis Primer. 4: 18014Oshima M Shimizu M Yamanouchi M et al.

Trajectories of kidney function in diabetes: a clinicopathological update.

Nat Rev Nephrol. 17: 740-750Lonati C Morganti A Comarella L Mancia G Zanchetti A Study Group IPERDIA

Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study.

J Hypertens. 26: 1801-1808

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.

Drugs. 75: 33-59Jaikumkao K Pongchaidecha A Chatsudthipong V Chattipakorn SC Chattipakorn N Lungkaphin A.

The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.

Biomed Pharmacother Biomedecine Pharmacother. 94: 176-187Sridhar VS Rahman HU Cherney DZI.

What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?.

Diabetes Obes Metab. 22 (): 55-68Abdel-Wahab AF Bamagous GA Al-Harizy RM et al.

Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.

Biomed Pharmacother Biomedecine Pharmacother. 103: 59-66Chen Z Li L Zhan Y et al.

Characterization and quantitative determination of henagliflozin metabolites in humans.

J Pharm Biomed Anal. 192113632Weng J Zeng L Zhang Y et al.

Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.

Diabetes Obes Metab. 23: 1754-1764Zhang YF Liu YM Yu C et al.

Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects following single- and multiple-dose administration.

Clin Ther. 43: 396-409Vasilakou D Karagiannis T Athanasiadou E et al.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Ann Intern Med. 159: 262-274Black HR Graff A Shute D et al.

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.

J Hum Hypertens. 11: 483-489Black HR Bailey J Zappe D Samuel R.

Valsartan: more than a decade of experience.

Drugs. 69: 2393-2414Durmus S Lozano-Mena G van Esch A Wagenaar E van Tellingen O Schinkel AH.

Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug-drug interactions in vivo.

Mol Pharm. 12: 4259-4269

Valsartan in chronic heart failure.

Ann Pharmacother. 39: 460-469Maeda K Ieiri I Yasuda K et al.

Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.

Clin Pharmacol Ther. 79: 427-439

Beijing Novartis Pharma Ltd. Instructions of Valsartan Capsules (Trade name: Daiwen).

Ayalasomayajula S Han Y Langenickel T et al.

In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).

J Clin Pharm Ther. 41: 424-431Mamidi RNVS Dallas S Sensenhauser C et al.

In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.

Br J Clin Pharmacol. 83: 1082-1096Hanna I Alexander N Crouthamel MH et al.

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.

Xenobiotica. 48: 300-313Wang L Wu C Shen L et al.

Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.

Xenobiotica Fate Foreign Compd Biol Syst. 46: 703-708Jangala H Vats P Khuroo AH Monif T.

Development and validation of a LC-MS/MS method for the simultaneous estimation of amlodipine and valsartan in human plasma: application to a bioequivalence study.

Sci Pharm. 82: 585-600

Center For Drug Evaluation. Technical Guidelines for Drug Interaction Studies (Draft). Accessed February 27, 2022.

Lee J Lee H Jang K Lim KS Shin D Yu KS.

Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.

Drug Des Devel Ther. 8: 1781-1788Seong SJ Ohk B Kang WY et al.

Pharmacokinetic drug interactions between amlodipine, valsartan, and rosuvastatin in healthy volunteers.

Adv Ther. 36: 1642-1656

Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.

Clin Ther. 35: 846-861Kasichayanula S Chang M Liu X et al.

Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.

Adv Ther. 29: 163-177Yong X Wen A Liu X et al.

Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus.

Clin Drug Investig. 36: 195-202Jung JA Lee SY Kim JR et al.

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.

Drug Des Devel Ther. 9: 745-752

Literature analysis of 74 cases of adverse reactions caused by valsartan.

Chin J New Drugs. 19 (): 1094-1096Qiu H Novikov A Vallon V.

Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives.

Diabetes Metab Res Rev. : 33

Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Diabetes Obes Metab. 23: 1111-1120